Moderator:
Andrew D. Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center

Panelists:
Ruben A. Mesa, MD
UT Health San Antonio Cancer Center

Neil P. Shah, MD, PhD
UCSF Helen Diller Family Comprehensive Cancer Center

William G. Wierda, MD, PhD
The University of Texas MD Anderson Cancer Center

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN Continuing Education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

The faculty listed below discloses the following relevant financial relationships:
Ruben A. Mesa, MD
ARIAD Pharmaceuticals, Inc.: Consulting Fees, Honoraria
Celgene Corporation: Grant/Research Support
CTI BioPharma Corp.: Grant/Research Support
Galena Biopharma, Inc.: Consulting Fees, Honoraria
Gilead Sciences, Inc.: Grant/Research Support
Incyte Corporation: Grant/Research Support
Novartis Pharmaceuticals Corporation: Consulting Fees, Honoraria
Promedior, Inc.: Grant/Research Support

Neil P. Shah, MD, PhD
ARIAD Pharmaceuticals, Inc.: Grant/Research Support
Bristol-Myers Squibb Company: Grant/Research Support
Daiichi- Sankyo Co.: Grant/Research Support
Pfizer Inc.: Grant/Research Support

William G. Wierda, MD, PhD
AbbVie Inc.: Consulting Fees, Honoraria; Grant/Research Support; Scientific Advisor
Acerta Pharma: Consulting Fees, Honoraria; Grant/Research Support; Scientific Advisor
Celgene Corporation: Consulting Fees, Honoraria; Scientific Advisor
Emergent BioSolutions Inc.: Consulting Fees, Honoraria; Grant/Research Support; Scientific Advisor
Genentech, Inc.: Consulting Fees, Honoraria; Grant/Research Support; Scientific Advisor
Genzyme Corporation: Consulting Fees, Honoraria; Scientific Advisor
Gilead Sciences, Inc.: Consulting Fees, Honoraria; Grant/Research Support; Scientific Advisor
GlaxoSmithKline: Consulting Fees, Honoraria; Grant/Research Support; Scientific Advisor
Juno Therapeutics: Grant/Research Support
Kite Pharma: Grant/Research Support
Merck & Co., Inc.: Consulting Fees, Honoraria; Scientific Advisor
Novartis Pharmaceuticals Corporation: Consulting Fees, Honoraria; Grant/Research Support; Scientific Advisor
Pharmacyclics: Consulting Fees, Honoraria; Grant/Research Support; Scientific Advisor
Roche Laboratories, Inc.: Consulting Fees, Honoraria; Grant/Research Support; Scientific Advisor
sanofi-aventis U.S.: Consulting Fees, Honoraria
Sunesis Pharmaceuticals, Inc.: Grant/Research Support
Xencor, Inc.: Grant/Research Support

Andrew D. Zelenetz, MD, PhD
Adaptive Biotechnologies: Consulting Fees, Honoraria
Amgen Inc.: Consulting Fees, Honoraria
BeiGene: Grant/Research Support
Bristol-Myers Squibb Company: Grant/Research Support
Celgene Corporation: Consulting Fees, Honoraria
Genentech, Inc.: Consulting Fees, Honoraria
Gilead Sciences, Inc.: Consulting Fees, Honoraria; Grant/Research Support
Janssen Pharmaceutica Products, LP: Consulting Fees, Honoraria; Grant/Research Support
MEI Pharma Inc.: Grant/Research Support
NanoString® Technologies, Inc.: Consulting Fees, Honoraria
Portola Pharmaceuticals, Inc.: Consulting Fees, Honoraria
Roche Laboratories, Inc.: Consulting Fees, Honoraria; Grant/Research Support
Takeda Pharmaceuticals North America, Inc.: Consulting Fees, Honoraria

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Kimberly Bayer; Robert W. Carlson, MD; Melissa Esplen; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Donald Harting, MA, ELS, CHCP; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Kimbro, MBA, CPA; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Melinda Somasekhar, PhD (employed by NCCN until October 30, 2017); Gary J. Weyhmuller, MBA, SPHR

The NCCN Clinical Information staff listed below, who has reviewed content, discloses no relevant financial relationships:
Mary Anne Bergman; Mary Dwyer, MS; Hema Sundar, PhD

Definitions
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use.  Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.